This patient population presents a challenging environment to obtain fusion due to their mechanical instability and biology,” says Andersen. “In Denmark the current surgical standard is the use of non-instrumented fusion in treating elderly patients with spinal stenosis and concomitant degenerative olisthesis. Patients with two-level DS achieved estimated fusion rates of 63% (34/54) with i-FACTOR peptide enhanced bone graft versus 18% (6/34) with allograft. Patients with 1-level DS achieved estimated fusion rates of 40% (29/72) with i-FACTOR peptide enhanced bone graft versus 21% (17/80) with allograft. Results demonstrated a 50% fusion rate (63/126) using i-FACTOR peptide enhanced bone graft compared to a 20% fusion rate (23/114) using allograft at one-year postoperative follow-up. In the single centre, double-blind, randomised IVANOS study, 98 patients (240 treated levels) age 60 and older with lumbar spinal stenosis (LSS) and concomitant degenerative olisthesis (DS) were treated with non-instrumented lumbar posterolateral spine surgery and received either i-FACTOR peptide enhanced bone graft or allograft. In the USA, i-FACTOR peptide enhanced bone graft was approved via a pre-market approval (PMA) in 2015 only for use in single level anterior cervical fusion procedures. i-FACTOR peptide enhanced bone graft was approved in the European Union in 2008 and in Australia in 2010 for use in the repair of bony voids or defects in orthopaedic applications throughout the skeletal system. In spinal fusion procedures, surgeons use bone graft to join and stabilise vertebrae. I-FACTOR peptide enhanced bone graft is based on proprietary synthetic small peptide (P-15) technology developed by Cerapedics to support bone growth through cell attraction, attachment and activation. The conclusions were presented by Mikkel O Andersen (Sector for Spine Surgery and Research, Middelfart Hospital, Denmark) at the 7 th Annual Global Spine Congress ( GSC 2–5 May, Singapore).

This is the result of the IVANOS study evaluating i-FACTOR peptide enhanced bone graft in lumbar posterolateral spinal surgery. The use of i-FACTOR peptide enhanced bone graft (Cerapedics) resulted in a 50% fusion rate, compared to a 20% fusion rate using allograft in patients with non-instrumented surgery. I-FACTOR peptide enhanced bone graft had a 30% higher fusion rate than allograft in patients with non-instrumented surgery

Ifactor surgery